ASH News Daily 2017 - Issue 3 - C-4
IBRUTINIB CLINICAL TRIALS
Enrollment a pathway
to knowledge
DIFFUSE LARGE B-CELL
LYMPHOMA (DLBCL), RELAPSED
OR REFRACTORY
KEY ELIGIBILITY CRITERIA
* Pathologically confirmed relapsed/refractory DLBCL
* Adequate hematologic, hepatic, and renal function
A phase 1b/2, open-label, multicenter study to evaluate the
safety and efficacy of ibrutinib in combination with lenalidomide
and rituximab in subjects with relapsed or refractory DLBCL
PCYC-1123-CA
(NCT02077166)
* One or more measurable disease sites on CT scan (>1.5 cm in
longest dimension)
* ECOG performance status of 0-1
* No medically apparent CNS lymphoma or
leptomeningeal disease
* No history of allogeneic stem-cell (or other organ)
transplantation
RENAL CELL CARCINOMA,
UROTHELIAL CELL CARCINOMA,
GASTRIC ADENOCARCINOMA,
COLORECTAL ADENOCARCINOMA-
RELAPSED/REFRACTORY
KEY ELIGIBILITY CRITERIA
* Pathologically confirmed renal cell carcinoma (clear
cell), urothelial carcinoma (transitional cell), gastric or
gastroesophageal junction (GEJ) adenocarcinoma, or K-RAS
wild-type EGFR-expressing colorectal adenocarcinoma
* Renal cell carcinoma: 1-4 previous lines of therapy; ECOG 0-1
(2 may be acceptable)
A phase 1b/2 study of ibrutinib combination therapy in selected
advanced gastrointestinal and genitourinary tumors
* Urothelial carcinoma: 1-2 previous lines of therapy; ECOG 0-1
* Gastric or GEJ adenocarcinoma: 1-3 previous lines of therapy;
ECOG 0-1
PCYC-1128-CA
(NCT02599324)
* Colorectal adenocarcinoma: 2 to 4 previous lines of therapy;
ECOG 0-1 (2 may be acceptable)
CHRONIC LYMPHOCYTIC
LEUKEMIA (CLL)/SMALL
LYMPHOCYTIC LYMPHOMA (SLL)
KEY ELIGIBILITY CRITERIA
* Adequate hematologic, hepatic, and renal function
* Clinical diagnosis of CLL/SLL
* Initiating treatment within ±30 days of enrollment with novel
therapies including oral kinase inhibitors (eg, inhibitors of BTK
[eg, ibrutinib]), inhibitors of BCL2 pathway [eg, venetoclax], or
PI3K [eg, idelalisib]), or with other anti-CLL therapies/regimens
approved at the time of patient enrollment
Observational patient registry
PCYC-1134M-CA
(NCT02582879)
* Should have life expectancy of >6 months
* Should not be receiving treatment in an interventional clinical
trial with a non-approved, investigational agent for CLL/SLL at
study entry
TM
The safety and efficacy of the investigational use of this product have not been determined. There is no guarantee that the
investigational uses listed will be tied with and/or approved for marketing by any regulatory agency.
FS:9.5"
F:10.5"
Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 3
ASH News Daily 2017 - Issue 3 - A-1
ASH News Daily 2017 - Issue 3 - A-2
ASH News Daily 2017 - Issue 3 - A-3
ASH News Daily 2017 - Issue 3 - A-4
ASH News Daily 2017 - Issue 3 - A-5
ASH News Daily 2017 - Issue 3 - A-6
ASH News Daily 2017 - Issue 3 - A-7
ASH News Daily 2017 - Issue 3 - A-8
ASH News Daily 2017 - Issue 3 - A-9
ASH News Daily 2017 - Issue 3 - A-10
ASH News Daily 2017 - Issue 3 - A-11
ASH News Daily 2017 - Issue 3 - A-12
ASH News Daily 2017 - Issue 3 - A-13
ASH News Daily 2017 - Issue 3 - A-14
ASH News Daily 2017 - Issue 3 - A-15
ASH News Daily 2017 - Issue 3 - A-16
ASH News Daily 2017 - Issue 3 - A-17
ASH News Daily 2017 - Issue 3 - A-18
ASH News Daily 2017 - Issue 3 - A-19
ASH News Daily 2017 - Issue 3 - A-20
ASH News Daily 2017 - Issue 3 - A-21
ASH News Daily 2017 - Issue 3 - A-22
ASH News Daily 2017 - Issue 3 - A-23
ASH News Daily 2017 - Issue 3 - A-24
ASH News Daily 2017 - Issue 3 - A-25
ASH News Daily 2017 - Issue 3 - A-26
ASH News Daily 2017 - Issue 3 - A-27
ASH News Daily 2017 - Issue 3 - A-28
ASH News Daily 2017 - Issue 3 - B-1
ASH News Daily 2017 - Issue 3 - B-2
ASH News Daily 2017 - Issue 3 - B-3
ASH News Daily 2017 - Issue 3 - B-4
ASH News Daily 2017 - Issue 3 - B-5
ASH News Daily 2017 - Issue 3 - B-6
ASH News Daily 2017 - Issue 3 - B-7
ASH News Daily 2017 - Issue 3 - B-8
ASH News Daily 2017 - Issue 3 - B-9
ASH News Daily 2017 - Issue 3 - B-10
ASH News Daily 2017 - Issue 3 - B-11
ASH News Daily 2017 - Issue 3 - B-12
ASH News Daily 2017 - Issue 3 - B-13
ASH News Daily 2017 - Issue 3 - B-14
ASH News Daily 2017 - Issue 3 - B-15
ASH News Daily 2017 - Issue 3 - B-16
ASH News Daily 2017 - Issue 3 - B-17
ASH News Daily 2017 - Issue 3 - B-18
ASH News Daily 2017 - Issue 3 - B-19
ASH News Daily 2017 - Issue 3 - B-20
ASH News Daily 2017 - Issue 3 - B-21
ASH News Daily 2017 - Issue 3 - B-22
ASH News Daily 2017 - Issue 3 - B-23
ASH News Daily 2017 - Issue 3 - B-24
ASH News Daily 2017 - Issue 3 - B-25
ASH News Daily 2017 - Issue 3 - B-26
ASH News Daily 2017 - Issue 3 - B-27
ASH News Daily 2017 - Issue 3 - B-30
ASH News Daily 2017 - Issue 3 - B-31
ASH News Daily 2017 - Issue 3 - B-32
ASH News Daily 2017 - Issue 3 - B-33
ASH News Daily 2017 - Issue 3 - B-34
ASH News Daily 2017 - Issue 3 - B-35
ASH News Daily 2017 - Issue 3 - B-36
ASH News Daily 2017 - Issue 3 - B-37
ASH News Daily 2017 - Issue 3 - B-38
ASH News Daily 2017 - Issue 3 - B-39
ASH News Daily 2017 - Issue 3 - B-40
ASH News Daily 2017 - Issue 3 - B-41
ASH News Daily 2017 - Issue 3 - B-42
ASH News Daily 2017 - Issue 3 - B-43
ASH News Daily 2017 - Issue 3 - B-44
ASH News Daily 2017 - Issue 3 - B-45
ASH News Daily 2017 - Issue 3 - B-46
ASH News Daily 2017 - Issue 3 - B-47
ASH News Daily 2017 - Issue 3 - B-48
ASH News Daily 2017 - Issue 3 - B-49
ASH News Daily 2017 - Issue 3 - B-50
ASH News Daily 2017 - Issue 3 - B-51
ASH News Daily 2017 - Issue 3 - B-52
ASH News Daily 2017 - Issue 3 - B-53
ASH News Daily 2017 - Issue 3 - B-54
ASH News Daily 2017 - Issue 3 - B-55
ASH News Daily 2017 - Issue 3 - B-56
ASH News Daily 2017 - Issue 3 - C-1
ASH News Daily 2017 - Issue 3 - C-2
ASH News Daily 2017 - Issue 3 - C-3
ASH News Daily 2017 - Issue 3 - C-4
ASH News Daily 2017 - Issue 3 - C-5
ASH News Daily 2017 - Issue 3 - C-6
ASH News Daily 2017 - Issue 3 - C-7
ASH News Daily 2017 - Issue 3 - C-8
ASH News Daily 2017 - Issue 3 - C-9
ASH News Daily 2017 - Issue 3 - C-10
ASH News Daily 2017 - Issue 3 - C-11
ASH News Daily 2017 - Issue 3 - C-12
ASH News Daily 2017 - Issue 3 - C-13
ASH News Daily 2017 - Issue 3 - C-14
ASH News Daily 2017 - Issue 3 - C-15
ASH News Daily 2017 - Issue 3 - C-16
ASH News Daily 2017 - Issue 3 - C-17
ASH News Daily 2017 - Issue 3 - C-18
ASH News Daily 2017 - Issue 3 - C-19
ASH News Daily 2017 - Issue 3 - C-20
ASH News Daily 2017 - Issue 3 - C-21
ASH News Daily 2017 - Issue 3 - C-22
ASH News Daily 2017 - Issue 3 - C-23
ASH News Daily 2017 - Issue 3 - C-24
ASH News Daily 2017 - Issue 3 - C-25
ASH News Daily 2017 - Issue 3 - C-26
ASH News Daily 2017 - Issue 3 - C-27
ASH News Daily 2017 - Issue 3 - C-28
ASH News Daily 2017 - Issue 3 - C-29
ASH News Daily 2017 - Issue 3 - C-30
ASH News Daily 2017 - Issue 3 - C-31
ASH News Daily 2017 - Issue 3 - C-32
https://www.nxtbookmedia.com